Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE).
Galetta D, Pisconti S, Cinieri S, Pappagallo GL, Gebbia V, Borsellino N, Maiello E, Rinaldi A, Montrone M, Rizzo P, Marzano N, Sasso N, Febbraro A, Colucci G. Galetta D, et al. Among authors: montrone m. Clin Lung Cancer. 2011 Nov;12(6):402-6. doi: 10.1016/j.cllc.2011.06.006. Epub 2011 Aug 10. Clin Lung Cancer. 2011. PMID: 21831718 Clinical Trial.
Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial.
Galetta D, Cinieri S, Pisconti S, Gebbia V, Morabito A, Borsellino N, Maiello E, Febbraro A, Catino A, Rizzo P, Montrone M, Misino A, Logroscino A, Rizzi D, Di Maio M, Colucci G. Galetta D, et al. Among authors: montrone m. Clin Lung Cancer. 2015 Jul;16(4):262-73. doi: 10.1016/j.cllc.2014.12.002. Epub 2014 Dec 9. Clin Lung Cancer. 2015. PMID: 25582493 Free article. Clinical Trial.
EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With Immunotherapy.
Prelaj A, Rebuzzi SE, Pizzutilo P, Bilancia M, Montrone M, Pesola F, Longo V, Del Bene G, Lapadula V, Cassano F, Petrillo P, Bafunno D, Varesano N, Lamorgese V, Mastrandrea A, Ricci D, Catino A, Galetta D. Prelaj A, et al. Among authors: montrone m. Clin Lung Cancer. 2020 Jul;21(4):365-377.e5. doi: 10.1016/j.cllc.2019.11.017. Epub 2020 Mar 7. Clin Lung Cancer. 2020. PMID: 32245624 Clinical Trial.
Esophageal Stricture Caused by ALK-Positive NSCLC Esophageal Metastasis Resolved After a Few Days of Lorlatinib Therapy Without Stent Placement.
Longo V, Catino A, Montrone M, Pizzutilo P, Ugenti I, Lacalamita R, Del Bene G, Pesola F, Marech I, Galetta D. Longo V, et al. Among authors: montrone m. JTO Clin Res Rep. 2020 Apr 18;1(2):100044. doi: 10.1016/j.jtocrr.2020.100044. eCollection 2020 Jun. JTO Clin Res Rep. 2020. PMID: 34589934 Free PMC article. No abstract available.
What Are the Biomarkers for Immunotherapy in SCLC?
Longo V, Catino A, Montrone M, Pizzutilo P, Annese T, Pesola F, Marech I, Cassiano S, Ribatti D, Galetta D. Longo V, et al. Among authors: montrone m. Int J Mol Sci. 2021 Oct 15;22(20):11123. doi: 10.3390/ijms222011123. Int J Mol Sci. 2021. PMID: 34681779 Free PMC article. Review.
54 results